All News
Filter News
Found 809,010 articles
-
Alnylam Reports Positive Topline Results from ILLUMINATE-A Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1
12/17/2019
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the ILLUMINATE-A Phase 3 study of lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase (GO) in development for the treatment of primary hyperoxaluria type 1 (PH1), met its primary efficacy endpoint and all tested secondary endpoints
-
Dr. Jie Jack Li joins Shanghai ChemPartner as a Vice President of Discovery Chemistry
12/17/2019
Shanghai ChemPartner announced the appointment of Jie Jack Li, Ph.D. as a Vice President of Discovery Chemistry at the Company headquarters in Shanghai, China.
-
CRH Medical Corporation Announces Majority Purchase of Florida Panhandle Anesthesia Associates
12/17/2019
Florida Panhandle is the company's sixth acquisition in the state of Florida and provides anesthesia services to a single GI ambulatory surgery center.
-
RAPID AI Enhanced Advanced Medical Imaging for Stroke Now Installed in Vietnam
12/17/2019
RAPID expands worldwide reach to bring Vietnam the only clinically validated, next-generation imaging platform for assessing stroke
-
ACRO Announces New Member and 2020 Officers
12/17/2019
The Association of Clinical Research Organizations (ACRO) is pleased to announce that its Board of Directors has elected Alistair Macdonald, Chief Executive Officer of Syneos Health, as 2020 Chair.
-
FDA permits sale of two new reduced nicotine cigarettes through premarket tobacco product application pathway
12/17/2019
The U.S. Food and Drug Administration today announced it has authorized the marketing of two new tobacco products manufactured by 22nd Century Group Inc. – Moonlight and Moonlight Menthol, which are combusted, filtered cigarettes that contain a reduced amount of nicotine compared to typical commercial cigarettes.
-
Avadel Pharmaceuticals Completes Enrollment in the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
12/17/2019
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it has completed patient enrollment in the REST-ON Phase 3 clinical trial for FT218.
-
Palo Alto Health Sciences Appoints Dean Sawyer as President and Chief Executive Officer
12/17/2019
Dean brings additional experience as a trusted partner and advisor for venture capital firms and startup incubators and accelerators.
-
Dicerna™ Receives Orphan Drug Designation From European Commission for DCR-A1AT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency
12/17/2019
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the European Commission (EC) has granted orphan drug designation to Dicerna’s DCR-A1AT for the treatment of congenital alpha-1 antitrypsin (A1AT) deficiency based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA)
-
Parvizi Surgical Innovation To Invest In Precision Hip Implantation Technology
12/17/2019
Parvizi Surgical Innovation, LLC (PSI) has made a minority investment in a development-stage hip replacement surgery device company, Navbit Holdings Pty Ltd, based in Sydney, Australia.
-
Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Significant Treatment Benefit for People with ALS in the CENTAUR Trial
12/17/2019
Study Meets Primary Endpoint of Slowing of ALS as Measured by the ALSFRS-R
-
Theraderm® Clinical Skincare Bolsters Supply To Meet Increased Demand For Industry Leading Skin Healing Formulas
12/17/2019
Therapon Skin Health, the makers of the medical grade skincare line Theraderm® Clinical Skin Care, announces the expansion of its clinically-proven, patented skincare solutions beyond plastic surgery centers.
-
Global Biopharmaceutical Company Chooses ValGenesis VLMS for Digitized, Audit-Ready Validation Lifecycle Processes Across Multiple Sites
12/17/2019
A premier biopharmaceutical company, this client provides high quality, life-saving and affordable biotherapeutics to patients across the world.
-
Chubb Introduces First-of-Its-Kind Financial Institution Fidelity Bond to Address Unique Risks Faced by Asset Managers
12/17/2019
Chubb has introduced a new fidelity insurance solution, the Financial Institution Bond for Asset Managers, to address the unique range of risks faced by today's asset managers.
-
Biohaven Achieves Positive Topline Results in Pivotal Phase 2/3 Study of Vazegepant, The First and Only Intranasal CGRP Receptor Antagonist in Clinical Development for the Acute Treatment of Migraine
12/17/2019
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced positive topline results from its randomized, dose ranging, placebo controlled, pivotal Phase 2/3 clinical trial (BHV3500-201; NCT03872453) evaluating the efficacy and tolerability of intranasal vazegepant 5, 10 and 20 mg versus placebo in 1,673 patients for the acute treatment of migraine.
-
Taro Announces Preliminary Results of Its Tender Offer
12/17/2019
These shares represent approximately 0.77% of the Company’s issued and outstanding ordinary shares as of December 16, 2019.
-
Bio-Techne's Exosome Diagnostics Lab Receives Accreditation From College of American Pathologists (CAP)
12/17/2019
Bio-Techne Corporation (NASDAQ:TECH) today announced that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to its Exosome Diagnostics (ExosomeDx) laboratory based on results of a recent on-site inspection as part of the CAP's Accreditation Program.
-
National Dropout Prevention Center Announces Nation's First Trauma-Skilled Specialist
12/17/2019
Melisa Sandoval of Westminster Public Schools in Colorado Earns Certification
-
Proteostasis Therapeutics Announces Positive Phase 2 Topline Results from Proprietary CFTR Modulator Combinations in F508del Homozygous Cystic Fibrosis Patients
12/17/2019
Proteostasis Therapeutics, Inc. (NASDAQ: PTI), today announced positive topline results from the Company's global, multicenter, randomized, placebo-controlled, 28-day, Phase 2 study evaluating its proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulator combinations in F508del homozygous and heterozygous CF subjects 18 years of age and older
-
Bulletin From the Extraordinary General Meeting in Oncopeptides AB (publ)
12/17/2019
An Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was held today, at Tändstickspalatset in Stockholm